Back to Search Results
 
Rodolfo Curiel Rodolfo Curiel
Associate Professor of Medicine

Office Phone: 202-741-2488
Email: Email
Department: Medicine

Education

  • BS, Colegio Nacional, 1974
  • MD, University of Buenos Aires, 1982

Biography

Rodolfo Curiel, MD, FACP, FACR is the Director of the Division of Rheumatology and Associate Professor of Medicine at GW School of Medicine and Health Sciences.

A native of Buenos Aires, Dr. Curiel graduated with a degree in Medicine from the University of Buenos Aires. After moving to Washington, DC, Dr. Curiel worked for three years at the National Institute of Health in Bethesda, MD as a visiting scientist conducting research related to cardiomyopathies and aortic valve disorders. Dr. Curiel pursued further residency and fellowship training in Internal Medicine at Providence Hospital and Rheumatology at the George Washington University. He has an active clinical practice caring for patients with autoimmune diseases.

Dr. Curiel is also the Director of The GW Myositis Center. The Center was created with the help of a generous grant from Cure JM, a nonprofit organization dedicated to finding a cure for juvenile-onset myositis. The center provides clinical consultation to patients with established or suspected inflammatory muscle diseases. The center has several ongoing research studies including Identifying Genetic Risk and protective Factors for Myositis, Outcome Studies in Juvenile and Adult Dermatomyositis and Polymyositis, Environmental Exposures and Disease Flare in Adult and Juvenile Dermatomyositis, physical function in juvenile myositis  and  clinical trials which focus on the response of myositis patients to different therapeutic agents.

Dr. Curiel's scientific contributions have been published in peer review journals, such as Lancet, Journal of The American College of Cardiology, Circulation, American Journal of Cardiology, Arthritis and Rheumatism, Journal of Clinical rheumatology, Annals of the New York Academy of Sciences and Seminars in Arthritis and Rheumatism. Dr. Curiel has presented his work at various local, national, and international conferences including the American College of Rheumatology Annual meeting and The Global Conference on Myositis (GCOM).

Dr. Curiel is a member of several professional societies, including The American College of Physicians and The American College of Rheumatology. He is certified in Rheumatology. He is also a member of the DC Rheumatism Society since 1999, Vice-President from 2008-2009, and President from 2009-2010. He has also been awarded as one of the Washingtonian magazine's Top Doctors consistently since 2008.

Post-Graduate Medical Training

Research Training:

  • Visiting Associate to the Cardiology Branch of The National Institutes of Health,  Bethesda, Maryland. (1993-1995)
  • Visiting Scientist to the Cardiology Branch of The National Institutes of Health, Bethesda, Maryland.(1995-1996)

Internship and Residency:

  • Providence Hospital, Washington, DC. Residency Internal Medicine (1996-1999)

Fellowship:

  • Division of Rheumatic Diseases The George Washington University, Washington, DC  (1999-2001) Rheumatology Fellowship.

Expertise

  • Inflammatory myopathies
  • Connective tissue disease
  • Rheumatoid Arthritis
  • Vasculitis 

Research

The GW Myositis Center has several ongoing research studies including Identifying Genetic Risk and protective Factors for Myositis, Outcome Studies in Juvenile and Adult Dermatomyositis and Polymyositis, Environmental Exposures and Disease Flare in Adult and Juvenile Dermatomyositis and Polymyositis, Physical Function in Juvenile Myositis and clinical trials which focus on the response of myositis patients to different therapeutic agents.

Featured Scientific Presentations

  1. Deakin CT, Bowes J, Rider LG, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel RV, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Wilkinson MG,1Eyre S, Raychaudhuri S, Wedderburn LR on behalf of the Juvenile Dermatomyositis Cohort and Biomarker Study, the Childhood Myositis Heterogeneity Study Group, and the Myositis Genetics Consortium (MYOGEN) Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis (accepted for presentation at the Global Conference on Myositis/GCOM/, Prague, Czech Republic, June 6-9, 2022).
  2. Curiel RV, Nguyen W, Mamyrova G, Awal H, Ehrlich A, Brindle K, Haji-Momenian S, Sheets R, Chin AY, Lu S, Gadina M, Kim H, Jones O, Rider LG. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis following Abatacept Therapy: Results of the Abatacept in Dermatomyositis (AID) Trial (accepted for presentation at the Global Conference on Myositis/GCOM/, Prague, Czech Republic, June 6-9, 2022).
  3. Coss S, Abdul Aziz R, Zhou D, Zhou B, Miller KE, Wu YL, Ardoin SP, Oberle E, Driest K, Al Ahmed O,  Patwardhan A, Akoghlanian S, Sivaraman V, Barber-Smiley F, Drew J, Spencer C, Pachman LM, Morgan GA,  Mamyrova G, Curiel RV, O'Hanlon T, Rider LG, Miller FW, Padyukov L, Lundberg I, Notarnicola A, Vencovský J, Stiburková B,  Kryštufková O, Yu C-Y. Complement C4 gene copy number variations and polymorphisms, autoantibodies, and clinical manifestations of juvenile dermatomyositis- a multi-center study (accepted for presentation at the Childhood Arthritis and Rheumatology Research Alliance /CARRA/, Annual Scientific Meeting, May 1-4, 2022).

  4. McBride E, Mamyrova G, Harris-Love M, Premkumar A, Koziol D, Yao J, Yao L, Shrader J, Jain M, Curiel RV, Miller FW, Rider LG. Preliminary Validation of Rectus Femoris Muscle Ultrasound in Idiopathic Inflammatory Myopathy Patients. Arthritis Rheum 2018; 70 (suppl 9).  
  5. Phillpotts M, Aleatany Y, Jones OY, Mamyrova G, Rider LG, Curiel RV. Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM). Arthritis Rheum 2018; 70 (suppl 9).
  6. Deakin CT, Bowes J, Wilkinson M, Marshall LR, Johnson-Moore CR, Mamyrova G,  Curiel RV,  Rouster-Stevens K, Schmeling H, Sanner H, Huber AM, Feldman BM, Reed AM, Pachman LM, Eyre S, Raychaudhuri S, and Wedderburn LR, on behalf of the Juvenile Dermatomyositis Cohort and Biomarker Study and MYOGEN. The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis. Pediatric Rheumatology 2018; 16 (Suppl 2); 52(011), p7 doi.org/10.1186/s12969-018-0265-6.
  7. G Mamyrova, L Wu, AM Huber, IN Targoff, RV Curiel, FW Miller, LG Rider for the Childhood Myositis Heterogeneity Study Group. Presentation Features and Misdiagnosis in anti-MDA5 Autoantibody (Ab) Associated Juvenile Dermatomyositis (JDM) (Mar 29, 2019).
  8. E McBride, G Mamyrova, M Harris-Love, A Premkumar, D Koziol, J Yao, L Yao, J Shrader, M Jain, RV Curiel, FW Miller, LG Rider. Preliminary Validation of Rectus Femoris Muscle Ultrasound in Juvenile Dermatomyositis (Mar 29, 2019).
  9. Mamyrova G, Kishi T, Targoff IN, Curiel RV, Miller FW, Rider LG. Anti-MDA5 autoantibody associated Juvenile dermatomyositis constitute a distinct phenotype in North America (podium presentation at the Japan College of Rheumatology 2019, Kyoto, Japan, April 17-20, 2019).
  10. Mamyrova G, Wu L, Huber AM, Targoff IN, Curiel RV, Miller FW, Rider RG. Presentation Features and Misdiagnosis in patients with anti-MDA5 Ab associated JDM (GWU Research Day April 10, 2019).
  11. E McBride, G Mamyrova, M Harris-Love, A Premkumar, D Koziol, J Yao, L Yao, J Shrader, M Jain, RV Curiel, FW Miller, LG Rider. Preliminary Validation of Rectus Femoris Muscle Ultrasound in Juvenile Dermatomyositis (accepted for a podium presentation at the DC Rheumatology Society Fellows Forum, May 15, 2019).

Leadership/National Membership

  • American College of Rheumatology, Fellow Member
  • American  College of Physicians, Fellow Member
  • International  Myositis Assessment & Clinical Studies Group, Member

Division

  • Rheumatology

Publications

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG; Abatacept in Dermatomyositis (AID) Trial Investigators.Arthritis Rheumatol. 2023 Jul;75(7):1229-1237. doi: 10.1002/art.42450. Epub 2023 Jun 7.PMID:36657109

Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies. Zhou D, King EH, Rothwell S, Krystufkova O, Notarnicola A, Coss S, Abdul-Aziz R, Miller KE, Dang A, Yu GR, Drew J, Lundström E, Pachman LM, Mamyrova G, Curiel RV, De Paepe B, De Bleecker JL, Payton A, Ollier W, O'Hanlon TP, Targoff IN, Flegel WA, Sivaraman V, Oberle E, Akoghlanian S, Driest K, Spencer CH, Wu YL, Nagaraja HN, Ardoin SP, Chinoy H, Rider LG, Miller FW, Lundberg IE, Padyukov L, Vencovský J, Lamb JA, Yu CY; for MYOGEN Investigators.Ann Rheum Dis. 2023 Feb;82(2):235-245. doi: 10.1136/ard-2022-222935. Epub 2022 Sep 28.PMID:36171069

Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Mamyrova G, McBride E, Yao L, Shrader JA, Jain M, Yao J,Curiel RV, Miller FW, Harris-Love MO, Rider LG.Rheumatology (Oxford). 2022 Apr 18;61(SI):SI48-SI55. doi: 10.1093/rheumatology/keab833.PMID:34791066

Association with HLA-DRß1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Deakin CT, Bowes J, Rider LG, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Ll Wilkinson MG, Eyre S, Raychaudhuri S, Wedderburn LR; Juvenile Dermatomyositis Cohort and Biomarker Study, the Childhood Myositis Heterogeneity Study Group, and the Myositis Genetics Consortium (MYOGEN).Hum Mol Genet. 2022 Jul 21;31(14):2471-2481. doi: 10.1093/hmg/ddac019.

Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.Rheumatology (Oxford). 2021 Apr 6;60(4):1839-1849. doi: 10.1093/rheumatology/keaa429.PMID:33140079

Long-term outcomes in Juvenile Myositis patients. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, Rider LG.Semin Arthritis Rheum. 2020 Feb;50(1):149-155. doi: 10.1016/j.semarthrit.2019.06.014. Epub 2019 Jun 28.PMID: 31303436

Treatment of calcinosis associated with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. Eleryan MG, Awosika O, Akhiyat S, Qureshi A, Rengifo-Pardo M, Curiel R, Rider LG, Ehrlich A.Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1092-1093. Epub 2019 Nov 18.PMID:31796160

Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.Rheumatology (Oxford). 2018 Nov 1;57(11):1956-1963. doi: 10.1093/rheumatology/key190.PMID:30016492

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None